Tech Company Financing Transactions
Ygion Biomedical Funding Round
Ygion Biomedical closed a $16 million Series A funding round on 5/23/2024. Investors included private investors.
Transaction Overview
Company Name
Announced On
5/23/2024
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to further develop its YGNITETM technology platform and advance the lead program YG-01 into preclinical and clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Campus Vienna Biocenter 5
Vienna, 1030
Austria
Vienna, 1030
Austria
Phone
Website
Email Address
Overview
Cancer is a leading global cause of death and emerges from healthy cells transforming into tumor cells due to genetic factors and external influences. Despite the variety of over 100 diseases it encompasses, current treatments remain limited and often bring unwanted side effects. We at YGION are committed to creating precision therapies eliminating tumors without harming patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wolfgang Fischl
Chief Operating Officer
Georg Casari
Chief Technical Officer
Geert Mudde
Co-Founder
Alexander Seitz
VP - Bus. Development
Sophie Zettl
VP - Regulatory Affairs
Gottfried Himmler
Browse more venture capital transactions:
Prev: 5/23/2024: Unlockit venture capital transaction
Next: 5/23/2024: Atropos Health venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries reported here come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs